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Image-guided (IG) intensity-modulated radiotherapy (IMRT) enables maximal tumormargin
reduction for the sparing of organs at risk (OARs) when used to treat locally advanced non-
small cell lung cancer (NSCLC) with definitive chemo-radiation. It also allows for the incor-
poration of stereotactic ablative radiotherapy (SABR) into the treatment regimen. Here, we
describe our initial experience in combining definitive upfront SABR to the primary lesion
with chemo-radiation delivered with conventionally fractionated IG-IMRT to the remaining
regional disease; along with clinical outcome following chemo-radiationwith conventionally
fractionated IG-IMRT alone in the treatment of locally advanced NSCLC.
Methods
The clinical outcome of 29 patients with locally advanced NSCLC who underwent conven-
tionally fractionated IG-IMRT, or definitive upfront SABR followed by IG-IMRT combined
with chemotherapy (induction, concurrent, or both) was retrospectively reviewed.
Results
After a median follow up of 23.7months, themedian overall survival (OS) and progression-free
survival (PFS)were 19.8 and 11.3months, respectively. The 2 year local, regional, and distant
control was 60%, 62%, and 38%, respectively. No local failure was observed in 3 patients fol-
lowing SABR + IG-IMRTwhile 6/26 patients failed locally following IG-IMRT alone. SABR + IG-
IMRT was well tolerated.No grade 3 radiation-related toxicity was observed.
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Conclusion
Definitive upfront SABR followed by IG-IMRT in selected patients with locally advanced
NSCLC warrants further investigation in future clinical trials, while chemo-radiationwith IG-
IMRT alone was well tolerated.
Introduction
In recent years, advances in technology such as 4DCT and intensity modulated radiotherapy
(IMRT) led to lower incidence of radiation-related toxicities and better short-term survival in
the treatment of locally advanced non-small cell lung cancer (NSCLC) with chemo-radiation
when compared to 3D techniques [1, 2]. Treatment accuracy and thoracic OAR sparing can be
further improved with daily image guidance due to more accurate tumor localization and the
safe PTV margin reduction it allows [3]. At the current time, image guided (IG)-IMRT may
represent one of the best radiotherapy delivery approaches in the treatment of locally advanced
lung cancer. With its advantages in OAR sparing, various strategies for radiation dose escala-
tion in the thorax become clinically feasible. As previously shown, dose escalation may increase
the tumor control probability in patients with locally advanced NSCLC, possibly leading to
improved survival [4, 5, 6]. Thus, effective dose escalation with IG-IMRT may represent an
important strategy to improve the clinical outcome in these patients. Given the negative results
obtained from RTOG 0617, a phase III randomized study assessing the benefit of moderate
dose escalation (conventionally fractionated) with 3D conformal radiotherapy (3D-CRT) or
IMRT in the patients receiving chemo-radiation for unresectable stage III NSCLC, similar
strategies of dose escalation with IG-IMRT has not been actively pursued. In RTOG 0617,
patients were randomized to chemo-radiation to 60 Gy vs. 74 Gy, and with or without Cetuxi-
mab [7]. While no survival benefit was obtained with the addition of cetuximab to the treat-
ment regimen in general, dose escalation resulted in inferior median survival (20.3 vs. 28.7
months, p = 0.004) and no improvement in local control at 2 years (61.4% vs. 69.3%, p = 0.13).
The causes of poorer outcome in the 74-Gy arms remain to be discerned. In theory, local con-
trol may be significantly decreased by delayed tumor cell repopulation associated with pro-
longed overall treatment time, which may be one reason for the lack of clinical benefit
observedwith moderate, conventionally-fractionated dose escalation [8]. This problem may be
solved by adopting alternative dose escalation strategies, such as stereotactic ablative radiother-
apy (SABR), to deliver a high dose to the tumor over a shorter overall treatment time course.
This is well evidencedby the clinical success of stereotactic ablative radiotherapy (SABR) in the
treatment of early stage NSCLC [9]. One unique strategy is to increase the tumor BED at the
primary site with definitive SABR, which is followed by conventionally fractionated chemo-
radiation to the remaining regional disease ± separate primary lesions in the same or other
lung lobes with IG-IMRT in certain patients with non-bulky regional nodal disease. In this
study, we describe our initial experiencewith this treatment approach along with our clinical
experiencewith chemo-radiation delivered with conventionally fractionated IG-IMRT.
Materials andMethods
Patient Selection
Twenty nine consecutive patients with stage II-IV NSCLC treated with IG-IMRT, including 3
patients treated with definitive upfront SABR to the primary site followed by IG-IMRT to the
SABR + IG-IMRT or IG-IMRT Alone for Locally Advanced NSCLC
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remaining disease, in the Department of Radiation Oncology of West Virginia University
(WVU) betweenOctober, 2012 and May, 2015 were included. This study was approved by
the WVU Institutional ReviewBoard under WVU research corporation office of research
integrity & compliance, and informed consent was not required due to its retrospective nature.
Although written consent was not signed by any patient, patient information was anonymized
and de-identified prior to any analysis. All patients’ diagnoses were pathologically confirmed.
All patients were staged with fluoro-deoxyglucosepositron emission tomography-computed
tomography (FDG PET/CT), and IV contrasted CT or MRI of the brain. The tumor, node, and
metastases staging system of the 7th edition of the American Joint Committee for Cancer Stag-
ing System was used for staging (AJCC 2010).
Treatment Planning
All patients treated with IG-IMRT alone were simulated supine while immobilized in alpha
cradles (Vac-Lok, CIVCO Medical Solutions, Coralville, IA) with the use of T-bars, wing
boards, and support for the head, shoulders, arms, and lower extremities. For patients who
were treated with SABR + IG-IMRT, they were immobilizedwith abdominal compression in
a dedicated SBRT immobilization device (CIVCO Medical Solutions, Coralville, IA) for
both portions of their radiotherapy with the use of T-bars, wing boards, and supports for the
head, shoulders, arms, and lower extremities. Patients were simulated with 4D CT or 4D
FDG PET/CT. Planning CTs were acquired with 3-mm slices. The gross tumor volume
(GTV) was delineated on the non-contrasted, free-breathing treatment planning CT. The
internal target volume (ITV) was contoured to include the tumor from all 10 phases of the
4D CT or 4D FDG PET/CT. Free breathing PET/CT was fused to the planning CT for ITV/
CTV delineation if 4D PET/CT was not done. For IG-IMRT, a 5–10 mm expansion was
used to create the CTV. The planning target volume (PTV) was the CTV plus a 3–5 mm
expansion. For SABR, ITV was directly expanded by 3–5 mm to create the PTV. The lungs,
esophagus, spinal cord, and the heart were contoured for each patient. Major vessels and air-
way were delineated if necessary. Target volume delineation and treatment planning were
both performed in the Eclipse treatment planning system (Varian Medical Systems, Palo
Alto, CA).
Treatment Delivery
Conventionally fractionated IG-IMRT treatments were delivered with either volumetric modu-
lated arc therapy (VMAT) using Rapid Arc, or regular multi-field IMRT with dynamic multi-
leaf collimator (MLC). 60–70 Gy (median: 63 Gy) was delivered in daily fractions of 1.8–2 Gy
with 6–10 MV photons. The majority of patients received concurrent chemotherapy with con-
ventionally fractionated IG-IMRT. OAR dose constraints used for IG-IMRT were the follow-
ing: total lung, V5< 65%, V20< 35%, mean lung dose (MLD)< 19 Gy; spinal cord, maximum
dose< 45 Gy; heart, V30< 50%, mean dose 35 Gy; esophagus, V55< 50%, mean dose 34
Gy, maximum dose< 105% of the prescription dose. For the 3 patients who received SABR &
IG-IMRT (Fig 1), SABR was delivered prior to IG-IMRT with 6 MV photons. The dose was
40–50 Gy delivered in 4 daily fractions. No systemic therapy was given during SABR delivery.
For these patients, the dose for conventionally fractionated IG-IMRT was 63 Gy delivered in
35 daily fractions. For SABR, the OAR dose was kept to as low as possible to keep the compos-
ite maximum dose to the spinal cord to 50 Gy, the esophagus and the heart to 70 Gy; and
the composite MLD to< 20–21 Gy. All treatments were delivered under daily image guidance
with cone beam CT.
SABR + IG-IMRT or IG-IMRT Alone for Locally Advanced NSCLC
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Follow Up
The patients were followed after 4 weeks, then every 3 months from the completion of all
radiotherapy with a history and physical examination, FDG PET/CT or CT of the chest every 3
months, and periodical basic laboratory studies, including the comprehensive metabolic panel,
complete blood count, and liver function tests for 2 years then every 3–6 months thereafter for
3 years. Treatment-related toxicity was assessed during each follow up visit with the National
Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0. Addi-
tional evaluation, including biopsies of suspected recurrence/metastasis,was done if indicated.
Pulmonary function tests are recommended to all patients 3 months after completion of their
radiotherapy.
Statistical Analysis
Descriptive statistical analysis was used to summarize the patients' characteristics, including
contingency tables with counts and percentages for categorical variables; mean (± s.d.) or
median (range) for continuous variables. Boxplot was used to summarize the heart’s mean
dose (MD), and the heart volume receiving 5 Gy (V5), 30 Gy (V30), and 40 Gy (V40) between
patient subgroups. Kaplan-Meier method was used to examine overall survival and progres-
sion-free survival functions including local, reginal and distant relapses. Log-rank test was used
Fig 1. Illustration of a composite treatmentplan for a patient with oligo-metastatic poorly
differentiated squamous cell carcinoma (cT1a, N3, M1b).She received upfront carboplatin/gemcitabine
with excellent extra-thoracic response. Subsequently, SABR to her primarydisease + IG-IMRT to her
regional disease as the only remaining disease following chemotherapy were administered. She remains
disease free 2 years after the completion of all treatments.
doi:10.1371/journal.pone.0162453.g001
SABR + IG-IMRT or IG-IMRT Alone for Locally Advanced NSCLC
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to assess the difference of time-to-event data between patient subgroups including stages,
mutation (yes/no), dose (high/low), and other baseline characteristic. A p-value< 0.05 was
considered statistically significant. Statistical analyses were carried out using SAS 9.1 (SAS
Institute, Cary, NC) and S-Plus, version 7.0 (Insightful Corp., Seattle, WA) software.
Results
Patient Characteristics
Patients’ clinical and treatment characteristics are listed in Table 1. 29 patients with primary
stage IIA-IIIB & oligo-metastatic stage IV, or recurrent NSCLC were included in this study.
Table 1. Patient Demographics andClinicalCharacteristics (n = 29 patients).
Characteristics # Patients (%)
















Squamous cell carcinoma 13 (44.8%)
Large cell carcinoma 1 (3.4%)
MedianRadiationdose (range)





Multi-field IMRT 8 (27.6%)
SABR (VMAT) + VMAT (#1) or IMRT (#2) 3 (10.3%)
Median treatment duration, minutes (range)
Image-guided IMRT 4.21 (1.81–12.67)
VMAT 3.72 (2.14–9.96)
Multi-field IMRT 5.05 (3.12–12.67)
SABR 17.55 (6.0–19.67)
Chemotherapy
Upfront (Sequential or Induction) 16 (55.2%)
Concurrent 25 (86.2%)
Median follow Up, months (range) 23.7 (5.3–32.0)
*2 recurrent IIIA, 2 recurrent IIIB
doi:10.1371/journal.pone.0162453.t001
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Among them, 93.1% were stage III (primary, or recurrent). The 4 patients with recurrent dis-
ease were initially treated with surgery ± adjuvant chemotherapy for stage I-III NSCLC. 26
patients received conventionally fractionated IG-IMRT alone, while 3 patients were treated
with SABR to the primary site combined with IG-IMRT to the remaining sites of disease. The
majority of patients received concurrent platinum-based chemotherapy during IG-IMRT (25
patients) or platinum-based chemotherapy prior to any radiotherapy (4 patients). Among the
patients who received concurrent chemotherapy, 12 patients also received induction chemo-
therapy. Two of the patients who were treated with SABR + IG-IMRT underwent chemother-
apy prior to any radiotherapy; while one received concurrent chemotherapy with IG-IMRT
after SABR delivery was completed.
Clinical Outcome
For all 29 patients, the median overall survival (OS) and progression-free survival (PFS) after a
median follow up of 23.7 months were 19.8 months and 11.3 months, respectively (Fig 2A and
2B). As shown, the 2-year OS and PFS were 38% and 29%. The majority of deaths were due to
distant progression (12/15 patients). Overall, the local, regional, and distant control rates at 2
years were 60%, 62%, and 38%, respectively. No local failure was observed in the 3 patients
who received definitive upfront SABR combined with IG-IMRT. Six local failures were
observed in patients who were treated with the conventionally fractionated IG-IMRT alone
combined with chemotherapy (concurrent, induction, or both). One of the three patients who
received SABR + IG-IMRT experienced regional and distant failures. Five patients experienced
regional failures, and 13 patients experienceddistant failures following IG-IMRT alone. The
local, regional, and distant control for patients who received SABR + IG-IMRT and those for
patients who received IG-IMRT are shown in Fig 2C–2E.
Fig 2. The a) overall survival (OS), and b) progression-free survival (PFS) for all patients. The c) local, d) regional,
and e) distant control for patients who were treatedwith SABR ± IG-IMRT. f) Local control following SABR
+ IG-IMRT vs. that in patients with Tx, T1/2 or T3/4 disease who received IG-IMRT.
doi:10.1371/journal.pone.0162453.g002
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Treatment-related Toxicity
Definitive upfront SABR + IG-IMRT was well tolerated without any acute or late grade 3
toxicity observed in all three patients. In the 26 patients who were treated with conventionally
fractionated IG-IMRT, no radiation-related pneumonitis was observedwhile the incidence of
grade 1–2 acute esophagitis was 53.8%. Grade 1–2 acute erythema in the treated areas was also
observed in 2 patients. No late toxicity was observed.The dosimetric factors for all patients are
shown in Table 2.
Discussion
In this study, the median survival was 19.8 months for all 29 patients with locally advanced
NSCLC. It appears to be similar to that observed in the MD Anderson study (1.8 years) on
patients with stage III-IV NSCLC treated to a median dose of 66 Gy in 33 daily fractions with
IMRT ± chemotherapy [2]. The local control was 60% at 2 years for all patients, which is
Table 2. Dosimetricparameters for patientswho received SABR + IG-IMRT (n = 29 patients).
IG-IMRT alone SABR + IG-IMRT
IG-IMRT SABR Composite
PTV dose coverage*
V100 95% (85%–100%) 96% (91%–100%) 96% (95%–99%)
V95 100% (94%–100%) 100% (100%–100%) 100% (100%–100%)
D95 100% (85%–103%) 100% (95%–102%) 101% (100%–103%)
Dmax 114% (108%–128%) 110% (108%–119%) 125% (123%–125%)
Dmin 82% (56%–97%) 94% (90%–99%) 93% (91%–95%)
Dmean 105% (102%–112%) 105% (104%–105%) 111% (110%–111%)
OAR doses*
Total lung dose
MLD 18.10 (7.42–20.73) Gy 11.26 (10.66–15.96) Gy 2.96 (1.45–5.02) Gy 16.28 (13.62–17.41) Gy
V5 64% (52%–76%) 55% (42%–62%) 10% (7%–19%) 63% (54%–64%)
V10 49% (17%–56%) 41% (34%–47%) 8% (3%–15%) 49% (43%–56%)
V20 31% (4%–36%) 21% (19%–29%) 4% (1%–9%) 31% (24%–37%)
Spinal cord
Dmax 43.17 (28.45–44.74) Gy 36.51 (36.27–38.00) Gy 7.84 (3.23–8.86) Gy 36.88 (36.42–39.32) Gy
Esophagus
Dmax 70.02 (53.59–76.39) Gy 60.47 (52.86–65.87) Gy 7.49 (4.13–10.15) Gy 63.76 (53.00–67.99) Gy
Dmean 28.00 (9.66–41.45) Gy 14.85 (12.97–22.01) Gy 1.01 (0.58–1.16) Gy 15.43 (13.98–23.17) Gy
V55 27% (0%–55%) 1% (0%–16%) 0% (0%–0%) 1% (0%–17%)
Heart
Dmax — 63.66 (54.61–65.78) Gy 11.44 (0.29–35.66) Gy 65.66 (55.18–65.83) Gy
Dmean 14.56 (2.61–37.00) Gy 3.38 (2.92–10.44) Gy 1.65 (0.04–5.42) Gy 8.34 (5.03–10.49) Gy
V5 61% (9%–100%) 15% (9%–52%) 7% (0%–41%) 52% (29%–67%)
V30 17% (0%–55%) 2% (1%–9%) 0% (0%–0.2%) 2% (1%–9%)
V40 10% (0%–46%) 1% (0.5%–3.49%) 0% (0%–0%) 1% (1%–4%)
Major blood vessels
Dmax — 69.05 (60.97–70.89) Gy 6.68 (5.05–11.47) Gy 74.30 (61.25–75.01) Gy
Major airway
Dmax — 66.30 (58.22–71.84) Gy 5.18 (0.47–6.23) Gy 69.27 (58.61–75.55) Gy
*median (range); D95, Dmax, Dmin, and Dmean for the PTV are presented as a percentage of the prescription dose.
doi:10.1371/journal.pone.0162453.t002
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similar to that observed in another study on IMRT ±chemotherapy to an average dose of 69.5
Gy for stage I-III NSCLC, the 2 year local control and OS in 39 patients with stage IIIA/B
NSCLC were 58% and 58%, respectively [10]. Despite similar local control, worse OS at 2 years
was observed in this study. However, no conclusion can be made regarding to the efficacy of
IG-IMRT due to this study’s small sample size. Nevertheless, the median survival appears to be
better than that observed in most phase III chemo-radiation trials for locally advanced NSCLC,
which is usually less than 18 months [3]. As shown in RTOG 9410, a phase III randomized
study assessing the benefit for concurrent vs. sequential chemo-radiation with 3D techniques;
the best median survival achieved was 17 months following concurrent chemo-radiation [11].
Our overall regional and distant control rates were 62% and 38% at 2 years. The high incidence
of regional and distant failures may be associated with the presence of bulky regional nodal dis-
ease and the inclusion of patients with relatively more advanced disease. High incidence of dis-
tant metastases following definitive chemo-radiation is fairly common in patients with locally
advanced NSCLC, which will need to be better addressed as lung cancer therapeutics evolves in
the future.
Patients who received definitive upfront SABR + IG-IMRT did not experience any severe
toxicity. No local failure following SABR was observed,while 6 of 26 patients who received
IG-IMRT alone failed locally. This suggests a local control benefit of delivering a high BED to
the primary tumor over a short period of time. As shown in the treatment of early stage
NSCLC with SABR, tumor BED of 100 Gy10 may lead to local control of> 90%, and increase
the OS in patients who are surgically operable [12]. When feasible, definitive upfront SABR
+ IG-IMRT may also be more effective than other regimens of moderate hypo-fractionation in
achieving a high rate of local control [5, 13–15]. This may potentially augment the efficacy of
conventional IG-IMRT in locally advanced NSCLC. One of the 3 patients experienced a
regional failure and brain metastases simultaneously 15 months after completion of sequential
chemo-radiation. She subsequently died from disease progression. Her regional disease was ini-
tially treated to 63 Gy in 35 daily fractions, which may be suboptimal for the control of her
regional disease. Our exploratory findings suggest that definitive upfront SABR to the primary
tumor followed by conventionally fractionated IG-IMRT to the remaining disease, enabled by
image guidance and intensity modulation,may be feasible in selected patients with locally
advanced NSCLC undergoing chemo-radiation. Its efficacy opt to be further investigated in
future clinical trials. Although the interplay between IMRT and respiratory motion has been a
concern, this can be mitigated through various motion management techniques, such as the
motion encompassing approach with 4D CT as previously discussed [16].
Factors such as large PTV and KRAS mutations in adenocarcinomas (all on codon 12) were
found to be associated worse OS (p< 0.05). PTV directly correlates with the tumor size, which
has been known to be associated with local control and survival [17, 18]. The negative prognos-
tic value of certain KRAS mutations in NSCLC, and their association with radio-resistance
have long been known [19–22]. The likely mechanism is the constitutive activation of its down-
stream pathways, leading to increased survival of tumor cells following irradiation [21, 22].
Furthermore, the MD (mean dose) of the heart, and volumes of the heart receiving 5 Gy, 30
Gy, and 40 Gy (V5, V30, and V40) for patients who were alive appeared to be lower than that for
patients who already died from disease progression. While no conclusion can be made due to
the small size of the current study, the implications of these findings warrant further investiga-
tion in larger studies.
As an exploratory study on the feasibility of definitive upfront SABR to be followed by
chemo-radiation delivered with IG-IMRT in the treatment of locally advanced NSCLC, its
major limitation is the small sample size. However, this study not only explores the potential
feasibility of a unique approach to treat locally advanced NSCLC, but also reports our
SABR + IG-IMRT or IG-IMRT Alone for Locally Advanced NSCLC
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institutional experiencewith IG-IMRT in the treatment of locally advanced NSCLC without
making any firm conclusions. Validation studies with larger sample size will be conducted in
the future to further define the role of definitive SABR + IG-IMRT in the treatment of locally
advanced NSCLC.
Conclusion
Our study demonstrates that definitive upfront SABR + IG-IMRT in the setting of chemo-radi-
ation for locally advanced NSCLC may be feasible and warrants further validation in future
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